Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829582 | 0.91 | CYP17A1 (0.39) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL573575 | 0.91 | NFKB1 (0.39) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL4603098 | 0.90 | GAA (0.39) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL1551115 | 0.85 | ALDH1A1 (0.40) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL28167286 | 0.78 | GAA (0.38) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL28960308 | 0.77 | BTK (0.38) | NFKB1NFKB2RELAALDH1A1KMT2A | |
| SCHEMBL2050426 | 0.75 | — | — | |
| SCHEMBL3344623 | 0.75 | GAA (0.36) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL28976941 | 0.74 | TSHR (0.35) | NFKB1NFKB2RELACA1CA2 | |
| SCHEMBL28269645 | 0.74 | NFKB1 (0.42) | NFKB1NFKB2RELACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117304183-A | Five-membered and six-membered nitrogen-containing compound, intermediate thereof, preparation method and application | 杭州圣域生物医药科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-115244037-A | Substituted triazinones as thyroid hormone receptor agonists | 上海诚益生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| WO-2020042972-A1 | UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE AND QUINAZOLINE OR QUINOLINE COMPOUND, COMPOSITION AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2020-03-05 | — | — | WO | disclosed |
| EP-2881384-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-06-10 | — | — | EP | disclosed |
| US-8524675-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2499120-A1 | NOVEL 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN INHIBITORS | Novadex Pharmaceuticals AB (SE) | 2012-09-19 | — | — | EP | disclosed |
| EP-2486044-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Achaogen, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| WO-2011044501-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-04-19 | — | — | WO | disclosed |
| WO-2010132839-A9 | AMINOGLYCOSIDE DOSING REGIMENS | ACHAOGEN, INC. (US) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011044501-A2 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2010042851-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-15 | — | — | WO | disclosed |
| EP-2170065-A1 | DIPHENYL SUBSTITUTED ALKANES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-7538134-B2 | Substituted arylpyrazoles | PFIZER INC. (US) | 2009-05-26 | — | — | US | disclosed |
| WO-2008156721-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20060287365-A1 | Substituted arylpyrazoles | ZOETIS LLC | 2006-12-21 | — | — | US | disclosed |
| US-20050192279-A1 | Pyridazinones as antagonists of alpha4 integrins | JANSSEN PHARAMACEUTICA, N.V. (BE) | 2005-09-01 | — | — | US | disclosed |
| US-4863903-A | RENIN ENZYME INHIBITORS, HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| US-4719288-A | HYPOTENSIVE | CIBA-GEIGY CORPORATION (US) | 1988-01-12 | — | — | US | disclosed |
| US-4613676-A | PEPTIDES | CIBA-GEIGY CORPORATION (US) | 1986-09-23 | — | — | US | disclosed |
| EP-0143746-A2 | 5-Amino 4-hydroxy-valeryl-substituted derivatives | CIBA-GEIGY AG (CH) | 1985-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287365-A1 | Substituted arylpyrazoles | CYP3A4, CYP3A43, CYP4B1 | NFKB1 3593/4885NFKB2 4191/4885RELA 4263/4885 |
| US-20050192279-A1 | Pyridazinones as antagonists of alpha4 integrins | ITGB4, ITGA4, ITGB5 | NFKB1 2274/4885NFKB2 2741/4885RELA 3369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.